MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Sarcomatoid

Less common than epithelioid mesothelioma, only 7% to 20% of mesothelioma are sarcomatoid. Often called the “wild” type because of it’s unpredictable nature.

Diagnostic accuracy of BRCA1-associated protein 1 in malignant mesothelioma: a meta-analysis

Oncotarget 2017 August [Link] Wang LM, Shi ZW, Wang JL, Lv Z, Du FB, Yang QB, Wang Y Abstract BACKGROUND: Conventional measurements are not always helpful in the diagnosis of malignant mesothelioma (MM). Increasing studies indicate that loss of BRCA1-associated protein 1 (BAP1) detected by immunohistochemistry (IHC) is a useful diagnostic marker for MM. In […]

Comments Off on Diagnostic accuracy of BRCA1-associated protein 1 in malignant mesothelioma: a meta-analysis

Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma

Comments Off on Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma

Evaluation of intracavitary administration of curcumin for the treatment of sarcomatoid mesothelioma

Oncotarget 2017 February [Link] Pouliquen DL, Nawrocki-Raby B, Nader J, Blandin S, Robard M, Birembaut P, Grégoire M Abstract A rat model of sarcomatoid mesothelioma, mimicking some of the worst clinical conditions encountered, was established to evaluate the therapeutic potential of intracavitary curcumin administration. The M5-T1 cell line, selected from a collection established from F344 […]

Comments Off on Evaluation of intracavitary administration of curcumin for the treatment of sarcomatoid mesothelioma

Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma

Human Pathology 2017 August 12 [Epub ahead of print] [Link] Inaguma S, Lasota J, Wang Z, Czapiewski P, Langfort R, Rys J, Szpor J, Waloszczyk P, Okoń K, Biernat W, Ikeda H, Schrump DS, Hassan R, Miettinen M Abstract Diffuse malignant mesothelioma of the pleura is a highly aggressive tumor typically associated with short survival. […]

Comments Off on Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma

The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: Evidence-Based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.

Human Pathology 2017 August 4 [Epub ahead of print] [Link] Marchevsky AM, et. al. Abstract Immunohistochemistry is used to distinguish sarcomatoid malignant mesotheliomas (SMM) from spindle cell and pleomorphic carcinomas (SPC) but there are no guidelines on how to interpret cases that show overlapping or equivocal immunohistochemical findings. A systematic literature review of the immunophenotype […]

Comments Off on The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: Evidence-Based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.

Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.

Archives of pathology and laboratory medicine 2017 July [Epub ahead of print] [Link] Husain AN et.al. Abstract CONTEXT: – Malignant mesothelioma (MM) is an uncommon tumor that can be difficult to diagnose. OBJECTIVE: – To provide updated, practical guidelines for the pathologic diagnosis of MM. DATA SOURCES: – Pathologists involved in the International Mesothelioma Interest […]

Comments Off on Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.

Association Between Clinicopathological Factors and Genomic Abnormalities Detected by FISH Analysis in Epithelioid Diffuse Malignant Pleural Mesothelioma.

International Journal of Surgical Pathology 2017 June [Epub ahead of print] [Link] Takeda M, Kasai T, Hatakeyama K, Nakai T, Itami H, Uchiyama T, IIzuka N, Maruyama H, Ohbayashi Abstract BACKGROUND: Abnormality of genes including 9p21 is known in malignant mesothelioma and we have examined the frequency of gene deletion and amplification using the fluorescence […]

Comments Off on Association Between Clinicopathological Factors and Genomic Abnormalities Detected by FISH Analysis in Epithelioid Diffuse Malignant Pleural Mesothelioma.

JQ1, a BET inhibitor, synergizes with cisplatin and induces apoptosis in highly chemoresistant malignant pleural mesothelioma cells

Current Cancer Drug Targets 2017 June 23 [Epub ahead of print] [Link] Zanellato I, Colangelo D, Osella D Abstract Malignant pleural mesothelioma (MPM) is an asbestos-associated tumor with poor prognosis and few therapeutic options. JQ1, a selective antagonist of BRD4, modulates transcription of oncogenes, including MPM chemoresistance-associated c-Myc and Fra-1. We investigated if JQ1 could […]

Comments Off on JQ1, a BET inhibitor, synergizes with cisplatin and induces apoptosis in highly chemoresistant malignant pleural mesothelioma cells

GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung

American Journal of Surgical Pathology 2017 June [Epub ahead of print] [Link] Berg KB, Churg A Abstract The separation of sarcomatoid and desmoplastic malignant mesotheliomas from sarcomatoid carcinomas of the lung metastatic to the pleura may be difficult, since both types of tumor can be morphologically similar and are frequently positive only for pan-keratin. GATA […]

Comments Off on GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung

Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists

Oncotarget 2017 May 11 [Epub ahead of print] [Link] Urso L, Cavallari I, Silic-Benussi M, Biasini L, Zago G, Calabrese F, Conte PF, Ciminale V, Pasello G Abstract Malignant Pleural Mesothelioma (MPM) is a chemoresistant tumor characterized by low rate of p53 mutation and upregulation of Murine Double Minute 2 (MDM2), suggesting that it may […]

Comments Off on Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists